IDEAYA Biosciences Stock Forecast, Price & News

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDYA stock has increased by 179.6% and is now trading at $13.56.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEAYA Biosciences or view MarketBeat's top 5 stock picks.

Wall Street analysts have given IDEAYA Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEAYA Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for IDEAYA Biosciences.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, November, 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $2.93 by $3.10.
View IDEAYA Biosciences' earnings history.

6 equities research analysts have issued 1 year price targets for IDEAYA Biosciences' stock. Their forecasts range from $12.00 to $28.00. On average, they expect IDEAYA Biosciences' share price to reach $22.67 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences.

Some companies that are related to IDEAYA Biosciences include CytoDyn (CYDY), Keros Therapeutics (KROS), Zealand Pharma A/S (ZEAL), Arcturus Therapeutics (ARCT), Ligand Pharmaceuticals (LGND), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Athenex (ATNX), Phathom Pharmaceuticals (PHAT), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Endo International (ENDP), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT) and Cytokinetics (CYTK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), The Boeing (BA), Xeris Pharmaceuticals (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

(IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.98%), BlackRock Inc. (3.08%), State Street Corp (0.72%), Platinum Investment Management Ltd. (0.67%), Squarepoint Ops LLC (0.23%) and Charles Schwab Investment Management Inc. (0.14%). Company insiders that own IDEAYA Biosciences stock include Alexandria Venture Investments, Bvf Partners L P/Il, Jason Throne, Mark Lackner, Paul A Stone, Timothy M Shannon, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends for IDEAYA Biosciences.

IDYA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold IDEAYA Biosciences company stock in the last year include Jason Throne, Mark Lackner, Paul A Stone, and Ventures Iv LP 5Am.
View insider buying and selling activity for IDEAYA Biosciences.

IDYA stock was purchased by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., BlackRock Inc., Point72 Asset Management L.P., Squarepoint Ops LLC, State Street Corp, California Public Employees Retirement System, Massachusetts Financial Services Co. MA, and Acadian Asset Management LLC. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Alexandria Venture Investments, Bvf Partners L P/Il, Paul A Stone, Timothy M Shannon, and Value Fund L P Biotechnology.
View insider buying and selling activity for IDEAYA Biosciences.

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IDYA stock can currently be purchased for approximately $13.56.

IDEAYA Biosciences has a market capitalization of $394.19 million. The company earns $-41,970,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. IDEAYA Biosciences employs 56 workers across the globe.

The official website for IDEAYA Biosciences is www.ideayabio.com.

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-6209 or via email at [email protected]